Etienne Vachon-Presseau

Etienne Vachon-Presseau

Auto-generated profile, based on publicly available information

Etienne Vachon-Presseau

McGill University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CTChristophe Tanguay-Sabourin
Christophe Tanguay-Sabourin
MFMatt Fillingim
Matt Fillingim
GGGianluca V. Guglietti
Gianluca V. Guglietti
AZAzin Zare
Azin Zare
MPMarc Parisien
Marc Parisien
EVEtienne Vachon-Presseau
Etienne Vachon-Presseau
Chronic pain is a complex condition influenced by a combination of biological, psychological and social factors. Using data from the UK Biobank (n = 493,211), we showed that pain spreads from proximal to distal sites and developed a biopsychosocial model that predicted the number of coexisting pain sites. This data-driven model was used to identify a risk score that classified various chronic pain conditions (area under the curve (AUC) 0.70–0.88) and pain-related medical conditions (AUC 0.67–0.86). In longitudinal analyses, the risk score predicted the development of widespread chronic pain, the spreading of chronic pain across body sites and high-impact pain about 9 years later (AUC 0.68–0.78). Key risk factors included sleeplessness, feeling ‘fed-up’, tiredness, stressful life events and a body mass index >30. A simplified version of this score, named the risk of pain spreading, obtained similar predictive performance based on six simple questions with binarized answers. The risk of pain spreading was then validated in the Northern Finland Birth Cohort (n = 5,525) and the PREVENT-AD cohort (n = 178), obtaining comparable predictive performance. Our findings show that chronic pain conditions can be predicted from a common set of biopsychosocial factors, which can aid in tailoring research protocols, optimizing patient randomization in clinical trials and improving pain management.

12 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
EVEtienne Vachon-Presseau
Etienne Vachon-Presseau
SBSara E. Berger
Sara E. Berger
TATaha B. Abdullah
Taha B. Abdullah
LHLejian Huang
Lejian Huang
GCGuillermo A. Cecchi
Guillermo A. Cecchi
AAA. Vania Apkarian
A. Vania Apkarian
The placebo response is universally observed in clinical trials of pain treatments, yet the individual characteristics rendering a patient a ‘placebo responder’ remain unclear. Here, in chronic back pain patients, we demonstrate using MRI and fMRI that the response to placebo ‘analgesic’ pills depends on brain structure and function. Subcortical limbic volume asymmetry, sensorimotor cortical thickness, and functional coupling of prefrontal regions, anterior cingulate, and periaqueductal gray were predictive of response. These neural traits were present before exposure to the pill and most remained stable across treatment and washout periods. Further, psychological traits, including interoceptive awareness and openness, were also predictive of the magnitude of response. These results shed light on psychological, neuroanatomical, and neurophysiological principles determining placebo response in RCTs in chronic pain patients, and they suggest that the long-term beneficial effects of placebo, as observed in clinical settings, are partially predictable.

9 September 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJulie Gonneaud
Julie Gonneaud
ABAlex T. Baria
Alex T. Baria
ABAlexa Pichet Binette
Alexa Pichet Binette
BGBrian A. Gordon
Brian A. Gordon
JCJasmeer P. Chhatwal
Jasmeer P. Chhatwal
SVSylvia Villeneuve
Sylvia Villeneuve
Resting state functional connectivity (rs-fMRI) is impaired early in persons who subsequently develop Alzheimer’s disease (AD) dementia. This impairment may be leveraged to aid investigation of the pre-clinical phase of AD. We developed a model that predicts brain age from resting state (rs)-fMRI data, and assessed whether genetic determinants of AD, as well as beta-amyloid (Aβ) pathology, can accelerate brain aging. Using data from 1340 cognitively unimpaired participants between 18–94 years of age from multiple sites, we showed that topological properties of graphs constructed from rs-fMRI can predict chronological age across the lifespan. Application of our predictive model to the context of pre-clinical AD revealed that the pre-symptomatic phase of autosomal dominant AD includes acceleration of functional brain aging. This association was stronger in individuals having significant Aβ pathology.

1 February 2020 in Brain
Verified
Journal Article
Closed access
PDF file
ABAlexa Pichet Binette
Alexa Pichet Binette
JGJulie Gonneaud
Julie Gonneaud
JVJacob W Vogel
Jacob W Vogel
RJRenaud La Joie
Renaud La Joie
PRPedro Rosa-Neto
Pedro Rosa-Neto
TGthe PREVENT-AD Research Group
the PREVENT-AD Research Group
Age being the main risk factor for Alzheimer’s disease, it is particularly challenging to disentangle structural changes related to normal brain ageing from those specific to Alzheimer’s disease. Most studies aiming to make this distinction focused on older adults only and on a priori anatomical regions. Drawing on a large, multi-cohort dataset ranging from young adults (n = 468; age range 18–35 years), to older adults with intact cognition (n = 431; age range 55–90 years) and with Alzheimer’s disease (n = 50 with late mild cognitive impairment and 71 with Alzheimer’s dementia, age range 56–88 years), we investigated grey matter organization and volume differences in ageing and Alzheimer’s disease. Using independent component analysis on all participants’ structural MRI, we first derived morphometric networks and extracted grey matter volume in each network. We also derived a measure of whole-brain grey matter pattern organization by correlating grey matter volume in all networks across all participants from the same cohort. We used logistic regressions and receiver operating characteristic analyses to evaluate how well grey matter volume in each network and whole-brain pattern could discriminate between ageing and Alzheimer’s disease. Because increased heterogeneity is often reported as one of the main features characterizing brain ageing, we also evaluated interindividual heterogeneity within morphometric networks and across the whole-brain organization in ageing and Alzheimer’s disease. Finally, to investigate the clinical validity of the different grey matter features, we evaluated whether grey matter volume or whole-brain pattern was related to clinical progression in cognitively normal older adults. Ageing and Alzheimer’s disease contributed additive effects on grey matter volume in nearly all networks, except frontal lobe networks, where differences in grey matter were more specific to ageing. While no networks specifically discriminated Alzheimer’s disease from ageing, heterogeneity in grey matter volumes across morphometric networks and in the whole-brain grey matter pattern characterized individuals with cognitive impairments. Preservation of the whole-brain grey matter pattern was also related to lower risk of developing cognitive impairment, more so than grey matter volume. These results suggest both ageing and Alzheimer’s disease involve widespread atrophy, but that the clinical expression of Alzheimer’s disease is uniquely associated with disruption of morphometric organization.

12 May 2025 in Nature Human Behaviour
Verified
Journal Article
Open access
PDF file
MFMatt Fillingim
Matt Fillingim
CTChristophe Tanguay-Sabourin
Christophe Tanguay-Sabourin
MPMarc Parisien
Marc Parisien
AZAzin Zare
Azin Zare
GGGianluca V. Guglietti
Gianluca V. Guglietti
EVEtienne Vachon-Presseau
Etienne Vachon-Presseau
Chronic pain is a multifactorial condition presenting significant diagnostic and prognostic challenges. Biomarkers for the classification and the prediction of chronic pain are therefore critically needed. Here, in this multidataset study of over 523,000 participants, we applied machine learning to multidimensional biological data from the UK Biobank to identify biomarkers for 35 medical conditions associated with pain (for example, rheumatoid arthritis and gout) or self-reported chronic pain (for example, back pain and knee pain). Biomarkers derived from blood immunoassays, brain and bone imaging, and genetics were effective in predicting medical conditions associated with chronic pain (area under the curve (AUC) 0.62–0.87) but not self-reported pain (AUC 0.50–0.62). Notably, all biomarkers worked in synergy with psychosocial factors, accurately predicting both medical conditions (AUC 0.69–0.91) and self-reported pain (AUC 0.71–0.92). These findings underscore the necessity of adopting a holistic approach in the development of biomarkers to enhance their clinical utility.

20 August 2019 in PLOS Biology
Verified
Journal Article
Open access
PDF file
EVEtienne Vachon-Presseau
Etienne Vachon-Presseau
SBSara E Berger
Sara E Berger
TATaha B Abdullah
Taha B Abdullah
JGJames W Griffith
James W Griffith
TSThomas J Schnitzer
Thomas J Schnitzer
AAA Vania Apkarian
A Vania Apkarian
Psychological and personality factors, socioeconomic status, and brain properties all contribute to chronic pain but have essentially been studied independently. Here, we administered a broad battery of questionnaires to patients with chronic back pain (CBP) and collected repeated sessions of resting-state functional magnetic resonance imaging (fMRI) brain scans. Clustering and network analyses applied on the questionnaire data revealed four orthogonal dimensions accounting for 56% of the variance and defining chronic pain traits. Two of these traits—Pain-trait and Emote-trait—were associated with back pain characteristics and could be related to distinct distributed functional networks in a cross-validation procedure, identifying neurotraits. These neurotraits showed good reliability across four fMRI sessions acquired over five weeks. Further, traits and neurotraits all related to the income, emphasizing the importance of socioeconomic status within the personality space of chronic pain. Our approach is a first step in providing metrics aimed at unifying the psychology and the neurophysiology of chronic pain applicable across diverse clinical conditions.